Fractyl Health Cuts Net Loss to $14.2 Million in Third Quarter
Key Facts
Fractyl Health reported a net loss of $14.2 million for the quarter ended September 30, 2026, compared with a loss of $45.6 million in the same period of 2025, according to results published by the company via Yahoo Finance. The narrower loss came as research and development expenses declined, despite an increase in general and administrative expenses. The company also attributed the year-over-year improvement to favorable changes in certain non-cash items and higher interest income. On November 6, the company announced that it would release its third-quarter results and provide business updates on November 12, 2026, at 4:30 p.m. Eastern Time. The results provide a financial update following the company's announcements of changes to its workforce and program priorities during October.
Research and development expenses were $12.5 million in the third quarter of 2026, compared with $17.5 million in the corresponding period of 2025, according to the results statement. General and administrative expenses, meanwhile, rose to $6.2 million from $5.2 million a year earlier. Fractyl said operating expenses declined by $4.0 million overall year over year. The divergence between the two items reflects lower research and development spending alongside an increase in general and administrative expenses. The figures do not include a separate explanation from the company for the increase in general and administrative expenses.
The company said the year-over-year improvement included a favorable non-cash change of $25.7 million in the fair value of warrant liabilities, and a $1.6 million reduction in the non-cash loss from changes in the fair value of debt. Interest income also increased by $0.1 million compared with the third quarter of 2025. Fractyl listed these items alongside a $4.0 million reduction in operating expenses among the factors that contributed to the lower net loss. The quarterly net loss fell to $14.2 million from $45.6 million. The cited factors include non-cash accounting changes as well as changes in expenses and interest income.
In October 2026, Fractyl announced it would reduce its workforce by approximately 45% and discontinue internal development of the Rejuva program, while directing resources to Revita. In an update issued on October 22, the company said its cash runway was expected to extend through the second quarter of 2027. It also forecast a reduction of approximately 50% in quarterly operating cash burn to about $8 million by the end of that quarter. These steps place the third-quarter results within a period of realigning the company's spending and resources. The cash runway and spending figures remain company forecasts, not realized figures for the coming period.
For Revita, the company is targeting submission of an FDA De Novo application in late fourth quarter 2026, according to its October 16 announcement. It also forecast publication of first-year data from the REMAIN-1 cohort in the first quarter of 2027. The company said potential clearance could come in late 2027, with a potential U.S. commercial launch in early 2028. It describes these dates as targets or possibilities within the program's regulatory and commercial pathway. In trading, GUTS closed at $0.8812 on November 11, compared with a close of $0.8107 on November 10, according to EL7 data.